We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 18, 2020

Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Myeloma

Blood Cancer Journal


Additional Info

Blood Cancer Journal
Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Myeloma: A Cytogenetic Subgroup Analysis of POLLUX
Blood Cancer J 2020 Nov 03;10(11)111, JL Kaufman, MA Dimopoulos, D White, L Benboubker, G Cook, M Leiba, J Morton, P Joy Ho, K Kim, N Takezako, P Moreau, HJ Sutherland, H Magen, S Iida, JS Kim, H Miles Prince, T Cochrane, A Oriol, NJ Bahlis, A Chari, L O'Rourke, S Trivedi, T Casneuf, M Krevvata, J Ukropec, R Kobos, H Avet-Loiseau, SZ Usmani, J San-Miguel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading